Last reviewed · How we verify
NCT04292964
Prognostic Factors of Patients With COVID-19
trial in SARS-CoV-2 in 201 participants. Completed in 13 March 2020.
13 March 2020
Quick facts
| Lead sponsor | Chongqing Medical University |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 201 |
| Start date | 1 March 2020 |
| Primary completion | 13 March 2020 |
| Estimated completion | 13 March 2020 |
| Sites | 1 location across China |
Conditions studied
- SARS-CoV-2 — all drugs for SARS-CoV-2 →
- Outcome, Fatal — all drugs for Outcome, Fatal →
Sponsor
Chongqing Medical University
Who can join
18 and older, any sex, with SARS-CoV-2 or Outcome, Fatal. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The outbreak of coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in China has been declared a public health emergency of international concern. Despite lower mortality rate, SARS-CoV-2 has killed more people than SARS and MERS and the number keeps growing. Epidemic studies have been well described clinical features of patients with COVID-19, with the disease severity being an independent predictor of poor outcome. However, there is still no research investigating the prognostic factors of patients with COVID-19.
Publications & conference data
7 peer-reviewed publications reference this trial (live from Europe PMC):
-
Prognostic value of NT-proBNP in patients with severe COVID-19.
Gao L, Jiang D, Wen XS, Cheng XC, et al · · 2020 · cited 196× · PMID 32293449 · DOI 10.1186/s12931-020-01352-w -
COVID-19: from epidemiology to treatment.
Pericàs JM, Hernandez-Meneses M, Sheahan TP, Quintana E, et al · · 2020 · cited 47× · PMID 32511724 · DOI 10.1093/eurheartj/ehaa462 -
COVID-19 under spotlight: A close look at the origin, transmission, diagnosis, and treatment of the 2019-nCoV disease.
Sheervalilou R, Shirvaliloo M, Dadashzadeh N, Shirvalilou S, et al · · 2020 · cited 45× · PMID 32452539 · DOI 10.1002/jcp.29735 -
Clinical characteristics and predictive value of lower CD4<sup>+</sup>T cell level in patients with moderate and severe COVID-19: a multicenter retrospective study.
Wen XS, Jiang D, Gao L, Zhou JZ, et al · · 2021 · cited 26× · PMID 33435865 · DOI 10.1186/s12879-020-05741-w -
Clinical characteristics and fatal outcomes of hypertension in patients with severe COVID-19.
Cheng X, Cai G, Wen X, Gao L, et al · · 2020 · cited 9× · PMID 33197882 · DOI 10.18632/aging.104019 -
Prognostic value of NT-proBNP in patients with severe COVID-19
Gao L, Jiang D, Wen X, Cheng X, et al · · 2020 · cited 1× · DOI 10.1101/2020.03.07.20031575 -
Clinical characteristics and predictive value of lower CD4+T cell level in patients with moderate and severe COVID-19: A multicenter retrospective study
Wen X, Jiang D, Gao L, Zhou Jz, et al · · 2021 · DOI 10.21203/rs.3.rs-46009/v4
Verify or expand the search:
- PubMed search for NCT04292964
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for SARS-CoV-2
Currently open trials in the same condition.
- NCT07266558 — A Study to Evaluate the Efficacy and Safety of mRNA-1283 and mRNA-1273 in Participants 50 to 64 Years of Age Without Hig · Phase 4 · recruiting
- NCT06684379 — Study on Safety and Efficacy of Two Doses of PRS CK STORM in the Modulation of the Cytokine Storm for the Treatment of A · Phase 1, PHASE2 · recruiting
- NCT06585241 — A Study to Investigate the Immunogenicity and Safety of mRNA COVID-19 Variant-containing Vaccine Formulations · Phase 4 · recruiting
- NCT05876377 — Use and Effectiveness of COVID-19 Vaccines Using State Vaccine Registries and Insurance Claims Data · active not recruiting
- NCT05799651 — Safety and Immunogenicity of Glycovax-002 Vaccine in Healthy Adults · Phase 1 · active not recruiting
Other Chongqing Medical University trials
Trials by the same sponsor.
- NCT07298889 — High PEEP in Noninvasive Ventilation Patients With Pneumonia or ARDS · NA · recruiting
- NCT07503509 — Physiological Study of High PEEP in Noninvasive Ventilation · NA · recruiting
- NCT06118671 — The Evaluation of Artificial Intelligence in Lifestyle Management of Diabetic Patients in Community · NA · unknown
- NCT06272032 — Prospective Multicenter Observational Study and Promotion of the Application of Focused Ultrasound in Allergic Rhinitis · EARLY_PHASE1 · unknown
- NCT05974566 — Efficacy and Safety of Finerenone in Heart Failure With Reduced Ejection Fraction · unknown
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04292964 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Chongqing Medical University
- Last refreshed: 17 March 2020
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04292964.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing